Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.42 |
| ▸ | CNR2 | P34972 | 9/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25745804 | 0.83 | CNR1 (0.49) | CNR1CNR2GLSKDM4EALDH1A1 | |
| SCHEMBL22932725 | 0.81 | GAA (0.46) | CNR1CNR2GLSKDM4EALDH1A1 | |
| SCHEMBL24007196 | 0.80 | CNR1 (0.41) | CNR1CNR2 | |
| SCHEMBL22932722 | 0.79 | CNR1 (0.44) | CNR1CNR2GLSKDM4E | |
| SCHEMBL9607545 | 0.79 | GAA (0.42) | CNR1CNR2GLSKDM4EALDH1A1 | |
| SCHEMBL12859230 | 0.78 | KCNJ6 (0.40) | GLSKDM4EALDH1A1GLAMEN1 | |
| SCHEMBL24006947 | 0.77 | TSHR (0.50) | CNR1CNR2GLSKDM4EALDH1A1 | |
| SCHEMBL24007195 | 0.77 | CNR1 (0.37) | CNR1CNR2 | |
| SCHEMBL4482731 | 0.76 | GLS (0.64) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL23954030 | 0.76 | KDM4E (0.54) | CNR1CNR2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CNR1 4118/4885CNR2 3981/4885GLS 1355/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | CNR1 4118/4885CNR2 3981/4885GLS 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.